Objective:
To support clinical development of the quantitative corneal cross-linking (qCXL) platform for non-invasive refractive vision correction.
Approach:
- Funding Details: TECLens closed a $10 million Series A2 extension financing, with participation from existing investors including Johnson & Johnson Innovation.
- Clinical Development: Proceeds will support the expansion of the first-in-human proof-of-concept program, generation of clinical data, development of the next-generation system, and preparation for investigational device exemption submission.
- Technology Overview: The CXLens System reshapes the cornea using personalized patterns of ultraviolet light without cutting or removing corneal tissue, creating molecular bonds to produce controlled changes in corneal shape.
Key Findings:
- The ongoing proof-of-concept study is evaluating qCXL in patients with refractive errors, focusing on presbyopia.
- The financing round was expanded due to additional investor interest.
Interpretation:
The funding reflects TECLens' progress in clinical studies and confidence in their technology.
Conclusion:
TECLens aims to advance its platform toward a fundamentally different approach to refractive vision correction.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
